Navigation Links
First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU
Date:3/18/2011

portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit http://www.bmrn.com.

Important Safety Information Prolonged exposure to elevated blood Phe levels in PKU patients can result in severe neurologic damage. The initiation of KUVAN therapy does not eliminate the need for careful monitoring of blood Phe levels and ongoing dietary management.

Some patients receiving KUVAN can experience significant drops in blood Phe levels. Patients should be monitored closely to ensure that blood Phe levels do not fall too low. Not all patients with PKU respond to treatment wit
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests
2. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
3. RAND study finds increase in piracy and terrorism at sea
4. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
5. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
6. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
7. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
8. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
9. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
10. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthTronics, Inc ., a ... products and services, announced that a poster related ... versus external beam radiotherapy (EBRT) is being presented ... Association (MAAUA) Annual Meeting in Baltimore, Maryland September ... Cryosurgery and External Beam Radiation as Treatments for ...
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... Ky. , Sept. 18, 2014  Neogen Corporation ... has entered into a strategic agreement with Merck Animal ... Program. The Igenity Dairy Heifer Program ... essential information on the genetic potential of replacement dairy ... a calf is born, and is an excellent tool ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2
... January 28 The Binding Site Limited,("The Binding ... company, today announces the publication of the first,international ... and management of multiple myeloma, a cancer of ... disorders. , The guidelines ...
... an announcement made recently by Astellas Pharma Inc., CV Therapeutics, ... received a letter dated November 13, 2008 from Astellas setting ... at a price of $16.00 per share, subject to due ... deliberation, with the assistance of its financial and legal advisors, ...
... PTS by Albemarle responds to the demand in ... 27 Leading specialty chemical company, Albemarle Corporation, ... company, Zymes LLC, have joined forces to scale-up ... The next generation technology promotes the clear ...
Cached Biology Technology:International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 3International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 4International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 5International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 6International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 7CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 2Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 3
(Date:9/19/2014)... which over thousands of years has adapted to the arctic ... makes the cold dangerous for you. , This is happening ... the cold provoking substance, called nonylphenol, comes from the use ... of being a endocrine disruptor, but when entering the worm ... to protect the cells in its body from cold damage. ...
(Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
(Date:9/18/2014)... A new GSA Bulletin study uses tree ... Puerco and Chaco Wash in northern New Mexico, USA. ... cedar and willow, investigators were able to precisely date ... then combined this data with aerial imagery, LiDAR, longitudinal ... these arroyos. , Arroyos are deep, oversized channels that ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3For legume plants, a new route from shoot to root 2Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... ever had trouble sleeping can attest to the difficulties at work ... for ideal health and productivity, but what if five to six ... negatively affected? A team of researchers at Brigham and Women,s ... yourself to be, that lack of sleep can influence the way ...
... People for the Ethical Treatment of Animals (PETA) Foundation ... today alleging that the European Chemicals Agency (ECHA) is ... investigating cases in which animal testing could be avoided ... complaints about maladministration in EU institutions and agencies, and ...
... Mass., July 26, 2012  Aware, Inc. (NASDAQ: AWRE ), ... today reported financial results for its second quarter ended June 30, ... was $5.3 million, a decrease of 10% compared to $5.9 million ... second quarter of 2012 was $369,000 compared to a loss of ...
Cached Biology News:The longer you're awake, the slower you get 2PETA files complaint with European ombudsman over animal testing for REACH 2Aware, Inc. Reports Second Quarter 2012 Financial Results 2Aware, Inc. Reports Second Quarter 2012 Financial Results 3Aware, Inc. Reports Second Quarter 2012 Financial Results 4Aware, Inc. Reports Second Quarter 2012 Financial Results 5Aware, Inc. Reports Second Quarter 2012 Financial Results 6
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
...
... Protein, 1. Based on the methodology ... kit gives essentially colorless backgrounds in ... Protein provides convenient, reproducible and sensitive ... in less than two hours.The visualization ...
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
Biology Products: